Vivesto AB
STO:VIVE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vivesto AB
Interest Income Expense
Vivesto AB
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vivesto AB
STO:VIVE
|
Interest Income Expense
kr3.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Interest Income Expense
-kr30.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-122%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Interest Income Expense
-kr19.7m
|
CAGR 3-Years
-452%
|
CAGR 5-Years
-92%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Interest Income Expense
-kr62m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-31%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Interest Income Expense
-kr862m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-32%
|
|
|
BioArctic AB
STO:BIOA B
|
Interest Income Expense
kr13.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vivesto AB
Glance View
Oasmia Pharmaceutical AB engages in the research and development of drugs. The company is headquartered in Solna, Stockholm. The company went IPO on 2005-01-01. The firm has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
See Also
What is Vivesto AB's Interest Income Expense?
Interest Income Expense
3.7m
SEK
Based on the financial report for Dec 31, 2023, Vivesto AB's Interest Income Expense amounts to 3.7m SEK.
What is Vivesto AB's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
222%
Over the last year, the Interest Income Expense growth was 222%.
